Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Immunotherapy in Melanoma

Breast Cancer

Gastrointestinal Cancer

Immunotherapy in Melanoma

Weber Highlights Potency of Adjuvant Nivolumab in Melanoma

Jeffrey S. Weber, MD, PhD, discusses the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.
Read More >>

Neoadjuvant Immunotherapy Emerges as a New Frontier

Adjuvant Nivolumab Approved in Europe for Melanoma

EU Panel Backs Adjuvant Nivolumab for Melanoma

FDA Accepts Application for Adjuvant Pembrolizumab for Stage III Melanoma

Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

View More Stories >>

View Conference Coverage

2018 State of the Science Summit on Hematologic Malignancies in Clayton

State of the Science Summit on GI Cancers in Newport Beach

2018 ESMO Congress

2018 State of the Science Summit on Hematologic Malignancies in Cleveland

2018 Lynn Sage Breast Cancer Symposium

Dr. Eggermont Discusses Impact of Pembrolizumab in Melanoma

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

Dr. Tarhini on Recent Practice-Changing Clinical Trials in Melanoma

Dr. Whitman on the Role of Pembrolizumab in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Advances in Treating Melanoma: Closing Thoughts

COMBI-AD: Dual-Targeted Therapy for Stage 3 Melanoma

Alternative Approaches to Treating Melanoma

Emerging Agents and Combinations for Advanced Melanoma

Considering Chemotherapy's Value in Melanoma

Melanoma: Mechanisms of Resistance to Therapy

Targeting NRAS Mutations in Metastatic Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Less Common Side Effects With Immunotherapy in Melanoma

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

Melanoma: Testing for Immunotherapy-Related Hepatotoxicity

Immunotherapy-Related Pulmonary Toxicities in Melanoma

Melanoma: Management of Dermatologic Toxicities

Overall Toxicities With Immunotherapy in Melanoma

Monotherapy Versus Combination Therapy Approaches in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Metastatic Melanoma: The New Millennium

Keith Flaherty, MD, moderates this discussion with Rene Gonzalez, MD, Jason Luke, MD, FACP, and Jeffrey Weber, MD, PhD. The panel of experts in melanoma research and treatment talk about the most recent advances in the field, and provide perspective on how to apply the newest data to individualize treatment strategies.

View Now

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approvals in CSCC, NSCLC, and Myeloma, Breakthrough Designation in Prostate Cancer, and More